PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

MD Anderson Research Highlights Special Edition: ESMO 2024

Featuring promising novel immunotherapies and targeted therapies, predictive biomarkers, and insights into COVID mRNA vaccines and immunotherapy responses

2024-09-10
(Press-News.org) ABSTRACTS: 510MO, 618MO, 1821MO, 71MO, 995MO

BARCELONA, Spain ― The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features upcoming oral presentations by MD Anderson researchers at the 2024 European Society for Medical Oncology (ESMO) Congress focused on clinical advances across a variety of cancer types.

In addition to the studies summarized below, forthcoming press releases will feature the following oral presentations:

Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors (Abstract 606O) NKT2152, a novel oral HIF-2α inhibitor, in participants with previously treated advanced clear cell renal carcinoma: Preliminary results of a Phase I/II study (abstract 1690O) Haloperidol and lorazepam for agitated delirium in patients with advanced cancer: A multicenter, double-blind, randomized clinical trial (Abstract 1476O) Information on all ESMO content from MD Anderson can be found at MDAnderson.org/ESMO.

Pembrolizumab provides lasting cancer control in patients with localized MSI-H/dMMR cancers (Abstract 510MO)
Cancers with defects in DNA mismatch repair have high microsatellite instability (MSI-H/dMMR) and are more responsive to immune checkpoint inhibitors. In a study led by Kaysia Ludford, M.D., and Michael Overman, M.D., researchers assessed the long-term effects of pembrolizumab in 35 patients with MSI-H/dMMR. After a median follow-up of nearly three years, the disease-free survival rate was 80% and the overall survival rate was 94%. Additionally, almost 40% of patients achieved complete responses, with their cancers becoming undetectable. In the non-operative group, most patients preserved their affected organs. Importantly, the study found clearance of circulating tumor DNA (ctDNA) during treatment was linked with better patient outcomes, suggesting that ctDNA could be a useful tool for monitoring treatment efficacy. These results highlight pembrolizumab's potential for long-term cancer control and organ preservation in this patient population. Ludford will present the findings Sept. 14.

Next-generation combination treatment demonstrates safety and early efficacy in CDK4/6-treated HR+ HER2- breast cancer (Abstract 618MO)
CDK4/6 inhibitors combined with endocrine therapy have improved survival outcomes for patients with HR+ HER2- metastatic breast cancer, but on-target toxicities and acquired resistance are common. A Phase Ib/II trial led by Timothy Yap, M.B.B.S, Ph.D., evaluated a novel combination of the next-generation CDK4-selective inhibitor, atirmociclib (formerly PF-07220060), and the first-in-class selective CDK2 inhibitor, PF-07104091, to investigate safety and whether the combination can overcome acquired resistance. Atirmociclib does not target CDK6, which has been associated with many of the known toxicities reported with the approved CDK4/6 inhibitors. In 26 heavily pretreated patients with metastatic breast cancer, the objective response rate was 27.8%, the disease control rate was 55.6% and the median progression-free survival was 8.3 months. The combination was well-tolerated and had a manageable safety profile overall, with neutropenia being the most common grade three or higher adverse event. Dose expansion arms of the trial are ongoing. Yap will present the findings Sept. 14.

Baseline cytokine levels may predict dyspnea treatment response (Abstract 1821MO)
Dyspnea, or breathlessness, is a common symptom among many patients with advanced cancer. Previous results from a trial led by David Hui, M.D., demonstrated that both high-dose dexamethasone and placebo improved dyspnea, but there was no significant difference between the two arms. In a secondary analysis of trial results, researchers evaluated blood samples from 45 trial patients to explore predictive biomarkers. Those treated with dexamethasone had significantly decreased levels of cytokines TNF, IL-6 and IL-8 over 14 days, unlike those treated with placebo. Higher baseline cytokine levels were associated with a greater reduction in dyspnea intensity in the dexamethasone group and a smaller reduction in the placebo group, highlighting their potential as predictive biomarkers. These findings may have implications for personalizing dexamethasone treatment and understanding the placebo response. Dr. Hui will present the final data Sept. 15.

New combination therapy shows efficacy in advanced melanoma (Abstract 71MO)
While checkpoint inhibitors provide significant clinical benefit for patients with metastatic melanoma, many still develop treatment resistance. In a Phase I/II trial, researchers led by Salah-Eddine Bentebibel, Ph.D., and Adi Diab, M.D., investigated an intratumoral injection of CD40 agonist sotigalimab combined with immunotherapy drug pembrolizumab in 32 untreated patients with melanoma. The combination achieved an objective response rate of 50% with a 91% disease control rate. The study demonstrated that sotigalimab effectively engaged the CD40 pathway, boosting the infiltration and activation of antigen-presenting cells. The combination led to a strong activation of both innate and adaptive immune responses at the injection site as well as throughout the body. Additional analyses showed a higher clonality of T cells associated with improved clinical outcomes. The combination was well-tolerated and safe, highlighting its potential as a treatment alternative for patients with metastatic melanoma. Diab will present the findings Sept. 16.

COVID mRNA vaccines associated with improved responses to immunotherapy in multiple cancers (Abstract 995MO)
Personalized mRNA vaccines have improved the effectiveness of immune checkpoint inhibitors in preclinical models. To investigate the possible effects of COVID mRNA vaccines, researchers led by Adam Grippin, M.D., Ph.D., and Steven Lin, M.D., Ph.D., analyzed data from more than 8,000 patients with various cancers. Patients who received a COVID mRNA vaccine within 100 days prior to their biopsies had a significant increase in the immune checkpoint protein PD-L1, which is targeted by several checkpoint inhibitors. Among patients with non-small cell lung cancer (NSCLC) who were treated with checkpoint inhibitors, those who received a COVID mRNA vaccine lived twice as long as those who did not. Patients with metastatic melanoma who received the vaccine also had better outcomes, including improved survival and a lower risk of disease progression. This study suggests that COVID mRNA vaccines may enhance cancer immunotherapy by increasing PD-L1 expression, leading to improved survival. Grippin will present the findings Sept. 16.

Read this press release in the MD Anderson Newsroom.

END


ELSE PRESS RELEASES FROM THIS DATE:

Appalachian State University chooses Figshare as its new institutional repository platform

Appalachian State University chooses Figshare as its new institutional repository platform
2024-09-10
Figshare, a leading provider of institutional repository infrastructure that supports open research, is pleased to announce that Appalachian State University has chosen Figshare as its new institutional repository platform to share, showcase and manage its research outputs. Appalachian State University (App State) – part of the University of North Carolina System – chose Figshare as its new repository platform to replace the NC DOCKS consortial repository, which was created in 2007 and is slated to shut down at the end of 2024. The team at App State wanted to ...

Drug treatment shows promise for dangerous snoring condition, obstructive sleep apnea

Drug treatment shows promise for dangerous snoring condition, obstructive sleep apnea
2024-09-10
Patients taking sulthiame, a drug currently in use for epilepsy, experienced a reduction in their symptoms of obstructive sleep apnoea (OSA), according to results of a clinical trial presented at the European Respiratory Society (ERS) Congress in Vienna, Austria [1].   Patients with OSA often snore loudly, their breathing starts and stops during the night, and they may wake up several times. Not only does this cause tiredness, but it can also increase the risk of high blood pressure, stroke, heart disease and type 2 diabetes. OSA is very common, but many people do not ...

Experimental blood test predicts risk for developing COPD, other severe respiratory diseases

2024-09-10
A scientific team supported by the National Institutes of Health (NIH) has created a preclinical blood test to identify adults most likely to develop severe respiratory conditions, including chronic obstructive pulmonary disease (COPD). The blood test analyzes 32 proteins that scientists determined accurately predicted an adult with an increased likelihood for requiring medical care for or dying from severe respiratory illness. The risk score was based on lung health data collected from nearly 2,500 U.S. adults over a 30-year period. The findings were published ...

Girls may start puberty early due to chemical exposure

2024-09-10
WASHINGTON—Girls exposed to certain endocrine-disrupting chemicals (EDCs) may be more likely to start puberty early, according to new research published in Endocrinology, the flagship basic science journal of the Endocrine Society. EDCs mimic, block or interfere with hormones in the body's endocrine system. There has been an alarming trend toward early puberty in girls, suggesting the influence of chemicals in our environment. Early puberty is associated with an increased risk of psychosocial problems, obesity, diabetes, cardiovascular disease, and breast cancer. “We conducted a comprehensive screen of 10,000 environmental compounds ...

Innovative delivery, access to care necessary to increase health equity for rural patients with heart disease

2024-09-10
The American College of Cardiology’s Quality Summit 2024 will feature several poster presentations regarding rural health delivery and access to care that offer insights into innovative strategies to increase health equity for all heart disease patients. Research examines door-in-door-out and door-to-balloon (D2B) times for heart attack patients at critical access hospitals, improving door-to-thrombolytics for heart attack patients at rural hospitals, remote cardiac rehabilitation to increase access, and improving communications technology for EMS with STEMI patients in rural areas. “Rurality creates unique challenges in delivering high quality cardiovascular ...

Study indicates delayed feedback enhances learning performance in individuals with traumatic brain injury

Study indicates delayed feedback enhances learning performance in individuals with traumatic brain injury
2024-09-10
East Hanover, NJ – September 10, 2024 – Kessler Foundation researchers have published a novel study exploring the effects of delayed feedback on learning in individuals with moderate-to-severe traumatic brain injury (TBI). The article, “Bypassing Striatal Learning Mechanisms Using Delayed Feedback to Circumvent Learning Deficits in Traumatic Brain Injury” (Doi: 10.1097/HTR.0000000000000947), was published online ahead of print on July 24, 2024, in The Journal of Head Trauma ...

PLOS and DTH-Lab partner to increase youth participation in science

2024-09-10
San Francisco, California, United States - The Public Library of Science (PLOS) and the Digital Transformations for Health Lab (DTH-Lab) today announced a strategic partnership between the organizations to increase youth participation in science to include mentorship opportunities, amplifying youth voices in scientific publishing and building a body of research in digital health citizenship with a mini-collection.   “This strategic partnership with DTH-Lab will ensure that youth is empowered ...

What’s really ‘fueling’ harmful algae in Florida’s lake Okeechobee?

What’s really ‘fueling’ harmful algae in Florida’s lake Okeechobee?
2024-09-10
Lake Okeechobee is the largest lake in Florida and the second largest in the Southeastern United States. Over the past two decades, blooms of blue-green algae (Microcystis) have emerged in the lake and have been flushed into nearby urban estuaries, causing serious environmental and public health issues. Excess nutrients from industries, agriculture and urban development – particularly nitrogen and phosphorus – are well-known causes of harmful algal blooms worldwide. Historically, Lake Okeechobee has only been considered to be impaired for phosphorus, ...

Soft cells: Rounded tile shapes echo those found in nature

Soft cells: Rounded tile shapes echo those found in nature
2024-09-10
Tiles that fill two- and three-dimensional spaces with no gaps—including triangles, squares, hexagons, cubes, and other polyhedra—are typically designed with sharp corners and flat faces (straight edges). Gábor Domokos and colleagues explore soft and curved two- and three-dimensional tiles that completely fill space with a minimal number of sharp corners, which they term “soft cells.” The authors demonstrate how to soften polyhedral tiles by systematically deforming edges. The resulting shapes echo those found in nature, including river estuaries, zebra stripes, muscle tissue, and the chambers of seashells, including the Nautilus. Biological structures ...

Unravel Biosciences and SynGAP Research Fund (SRF) Announce clinical research to accelerate new and repurposed therapies for SYNGAP1-related disorders

Unravel Biosciences and SynGAP Research Fund (SRF) Announce clinical research to accelerate new and repurposed therapies for SYNGAP1-related disorders
2024-09-10
Mill Valley, CA – September 10, 2024 – The SynGAP Research Fund 501(c)(3) announced a collaboration with Unravel Biosciences, Inc., an AI-enabled therapeutics company, to initiate a clinical study aimed at generating primary clinical data, uncovering novel therapeutic targets, repurposing existing drugs, and stratifying SYNGAP1-Related Disorders (SRD) patients into subgroups based on their predicted response to selected drugs. This collaboration will utilize Unravel’s rareSHIFT™ discovery services and BioNAV™ AI platform to advance the development of targeted therapies for SRD. As part of this ...

LAST 30 PRESS RELEASES:

Transparent mesoporous WO₃ film enhances solar water splitting efficiency and stability

Protostellar jet detection in Milky Way’s outer region reveals universal star formation

New research uncovers a ‘ghost’ of the Australian bush

Study establishes link between rugby and dementia

Can courts safeguard fairness in an AI age?

Less than half of England has access to Mounjaro on the NHS months after roll-out

Study highlights cultural differences in parenting and reveals that how babies are soothed matters more than how fast

Claims on baby food fail to stack up

Potential molecular link between air pollutants and increased risk of Lewy body dementia revealed

Deaths from high blood pressure-related kidney disease up nearly 50% in the past 25 years

U.S. survey finds salt substitutes rarely used by people with high blood pressure

Researchers map key human proteins that power coronavirus replication, pointing to new treatment strategies

Single hair strand could provide biomarker for ALS, Mount Sinai study finds

Bio-oil made with corn stalks, wood debris could plug orphaned fossil fuel wells

Can the 'good' bacteria in your mouth act as probiotic cavity fighters?

This common fish has an uncommon feature: Forehead teeth, used for mating

UI Health performs first islet cell transplant with Lantidra

Study shows not all dietary proteins are digested the same way

MSU study finds accessible wireless ultrasounds are accurate

Scientists review breakthrough methods to disrupt toxic “forever chemicals” in water

Ghost sharks grow forehead teeth to help them have sex

How stress and social struggles fuel America’s obesity crisis

Researchers uncover similarities between human and AI learning

Researchers achieve light-induced heterolytic hydrogen dissociation at ambient temperature

Intestinal surface cells pull rather than push

Game-changing biotech for engineering pathogen-resistant crops

Evolution of rodents’ unique thumbnail contributed to their successful radiation

Estrogen-driven cell regeneration shields female kidneys from disease

Artificial intelligence helps boost LIGO

The promise and tradeoffs of the 'drone revolution' in modern agriculture

[Press-News.org] MD Anderson Research Highlights Special Edition: ESMO 2024
Featuring promising novel immunotherapies and targeted therapies, predictive biomarkers, and insights into COVID mRNA vaccines and immunotherapy responses